Therapy of Rituximab in Idiopathic Membranous Nephropathy with Nephrotic Syndrome: A Systematic Review and Meta-analysis
Conclusions RTX treatment in IMN was efficient, well tolerated and safe. More than 60% patients can reach partial remission or CR in 24 months, and relapse is rare. Adverse events of RTX are mostly infusion-related reactions and generally mild.
Source: Chinese Medical Sciences Journal - Category: General Medicine Source Type: research
More News: China Health | Cholesterol | Clinical Trials | Databases & Libraries | General Medicine | Italy Health | Nephrotic Syndrome | Proteinuria | Rituxan | Study | Urology & Nephrology